Areta International S.r.l.

Abiogen Pharma S.p.a.

Maria Luisa Nolli

Silvia Trasciatti

Riccardo Dolcetti

Luigi Cavenaghi

Massimo Guidoboni

Valli De Re

Daniela Gasparotto

Sonia Castiglioni

Alfredo Fusco

Antonio Orlandi

Nadia De Bernardi

The invention concerns the use of recombinant clonotypic immunoglobulins (Ig) as a vaccine in the treatment of HCV-related and non HCV-related lymphoproliferations, in particular the use of recombinant proteins with immunogenic properties derived from protein segments VK3-20 and VK3-15 of Ig light chains derived from patients with lymphoproliferations.

Idiotypic vaccine

This invention concerns a panel of monoclonal antibodies against the High Mobility Group A 1 protein (HMGA1) and a process for preparing them, as well as the use of said antibodies for the quantitative determination of HMGA1 in biological fluids or in protein Iy sates deriving from lymphocyte cells. This invention also concerns a diagnostic kit for assessing risk factors related to the expression of the HMGA1 proteins.

Anti-HMGA1 monoclonal antibodies, process for their preparation and their use for the quantitative determination of HMGA1

The present invention refers to a procedure for the large-scale amplification of human lymphocytic cell lines for therapeutic use, consisting of a homogeneous culture system. The claimed invention also refers to the production of therapeutic doses of lymphocytic cells cultured homogeneously.

Procedure for the large-scale T-lymphocytes culture in a homogeneous system

Growing community of inventors

Milan, Italy

Maria Luisa Nolli